Similar articles

• The safety of incretin based drugs.

  Montori VM. Montori VM. BMJ. 2014 Apr 24;348:g2779. doi: 10.1136/bmj.g2779. BMJ. 2014. PMID: 24764568 No abstract available.
• [DPP-4 inhibitors in clinical use. Therapy without the risk of hypoglycaemia].

  Gallwitz B. Gallwitz B. Pharm Unserer Zeit. 2010 Mar;39(2):114-8. doi: 10.1002/pauz.201000358. Pharm Unserer Zeit. 2010. PMID: 20196038 Review. German. No abstract available.
• Antihyperglycaemic therapy in elderly patients with type 2 diabetes: potential role of incretin mimetics and DPP-4 inhibitors.

  Mathieu C, Bollaerts K. Mathieu C, et al. Int J Clin Pract Suppl. 2007 Aug;(154):29-37. doi: 10.1111/j.1742-1241.2007.01437.x. Int J Clin Pract Suppl. 2007. PMID: 17593275 Review.
• Incretin therapy and its effect on body weight in patients with diabetes.

  Lind M. Lind M. Prim Care Diabetes. 2012 Oct;6(3):187-91. doi: 10.1016/j.pcd.2012.04.006. Epub 2012 May 19. Prim Care Diabetes. 2012. PMID: 22613745 Review.
• Novo Nordisk replies to BMJ investigation on incretins and pancreatic damage.

  Moses A. Moses A. BMJ. 2013 Jul 10;347:f4386. doi: 10.1136/bmj.f4386. BMJ. 2013. PMID: 23842435 No abstract available.